We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 20, 2022

Survival Outcomes and Predictive Biomarkers in Patients With HER2-Positive Breast Cancer Receiving Neoadjuvant Therapy

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Survival outcomes, digital TILs and on-treatment PET/CT during neoadjuvant therapy for HER2-positive breast cancer: results from the randomized PREDIX HER2 trial
Clin. Cancer Res 2022 Nov 30;[EPub Ahead of Print], A Matikas, H Johansson, P Grybäck, J Bjöhle, B Acs, C Boyaci, T Lekberg, H Fredholm, E Elinder, S Margolin, E Isaksson-Friman, A Bosch, H Lindman, J Arda, A Andersson, S Agartz, M Hellström, I Zerdes, J Hartman, J Bergh, T Hatschek, T Foukakis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading